Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]        
Product Revenue
Product Cost of Sales
Gross Income
Administrative Expenses 1,640,540 884,529 4,601,853 2,045,422
Research and Development Expenses 2,767,663 908,119 5,437,147 1,435,696
Interest Expense and Debt Discount 213,648 701,090 582,458
Amortization of Intangible Assets 4,583 9,167
Stock Option Modification Expenses 1,112,156 15,036,051 1,127,156
Loss from Operations (4,408,203) (3,123,035) (25,776,141) (5,199,899)
Other (Income) Expenses        
Interest and Dividend Income (1,714) (135) (7,355) (141)
(Gain)/Loss on Sale of Marketable Securities 1,100 (40,347)
Unrealized Loss on Marketable Securities 848 42,295
Loss on Currency Conversions 758 758
Uninsured Casualty Loss 1,058,086 1,058,086
Gain on Debt Forgiveness (180,257)
Total Other (Income) Expense 1,059,078 (135) 873,180 (141)
Loss Before Income Tax (5,467,281) (3,122,900) (26,649,321) (5,199,758)
Income Tax Benefit
Net Loss $ (5,467,281) $ (3,122,900) $ (26,649,321) $ (5,199,758)
Basic and Diluted loss per common share $ (0.15) $ (0.11) $ (0.78) $ (0.19)
Weighted average basic and diluted common shares outstanding 37,634,747 28,269,692 34,064,914 28,066,574